Bextra Lawsuit Attorney
Bextra Lawsuit Attorney
Pfizer withdrew Bextra from the U.S. market in April 2005 on the recommendation of the FDA. Introduced in November 2001, this non-steroidal anti-inflammatory drug was used to treat pain, stiffness, and inflammation associated with arthritis and other ailments. However, a number of research reports and government reviews held the drug responsible for causing rare skin reactions and increased risk of fatal cardiovascular problems in users.
Bextra was the second Cox-2 inhibitor to be withdrawn from the market after the Vioxx recall in 2004. Some of the side effects of the drug includes increased risk of heart attack, stroke, rare skin disease called Stevens–Johnson syndrome.
In October 2004, Pfizer acknowledged the cardiovascular side effects of Bextra. A report presented to the American Heart Association also highlighted that patients using Bextra were 2.19 fold more likely to suffer heart attack or stroke. A study published by the University of Pennsylvania in November claimed that Bextra posed greater risk of heart attack and stroke than Vioxx, which was withdrawn a month before the report had been made public.
In December 2004, the FDA issued a public health advisory asking doctors to limit use of Bextra and diagnose heart patients properly before prescribing the drug. Four months later, the federal regulator ordered Pfizer to immediately stop selling Bextra, citing major heart and skin problems caused by the drug. The European Union and Canada also suspended the sale of the drug with immediate effect. In December 2005, Health Canada banned Bextra on the recommendations of an expert panel.
In March 2009, a former sales manager from Boston pleaded guilty to selling Bextra inappropriately. She had directed 100 sales representatives working under her supervision to promote the drug for reasons rejected by the FDA. About half a dozen whistleblowers followed the suit and disclosed the unlawful practices adopted by Pfizer for marketing Bextra to the federal investigators.
Bextra Side Effects
The FDA has received reports of 87 cases of severe skin reactions, including four deaths, linked to Bextra. Stevens-Johnson Syndrome, a toxic epidermal necrolysis disorder, is the most prominent side effect of the drug. Many patients found themselves affected with the syndrome within two weeks of taking the drug. This complex syndrome affects the skin and mucous membranes, leading to rashes, mucosal lesions, and cell death.
Cardiovascular Side Effects